{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:48:08Z","timestamp":1794862088739,"version":"4.9.1"},"reference-count":167,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>B-cell maturation antigen (BCMA)\u2013 or G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013directed T-cell immunotherapies have substantially improved the survival of patients with relapsed\/refractory multiple myeloma (MM). Despite these advances, a subset of patients does not respond, and most patients will eventually relapse. Tumor heterogeneity, resulting in rapid selection of both antigen-negative and antigen-low cells, is a critical issue affecting response to T-cell immunotherapies targeting single tumor-associated antigens. In addition, antigen escape (due to deletions, mutations, or epigenetic alterations) is frequently observed in patients who experience disease progression after chimeric antigen receptor (CAR) T-cell infusion or during bispecific antibody (BsAb) treatment. Simultaneous targeting of 2 tumor-associated antigens may improve efficacy by addressing heterogeneous target expression and preventing antigen escape. Various dual-targeting strategies are currently evaluated in MM, including the combination of 2 single-antigen\u2013targeting BsAbs. Of note, the efficacy of the combination of teclistamab and talquetamab appears to have enhanced anti-MM activity, compared with the corresponding conventional BsAbs alone in similar patient populations. Furthermore, dual-antigen targeting with T-cell\u2013redirecting trispecific antibodies (eg, ramantamig [BCMA\u00d7GPRC5D] and ISB 2001 [BCMA\u00d7CD38]) has already demonstrated promising results in heavily pretreated MM. Studies with limited numbers of patients have demonstrated that CAR T-cell products with specificity for &amp;gt;1 antigen are also effective in advanced MM; however, at this time, none of the dual-targeting CAR T-cell products has been shown to be clearly superior to targeting BCMA alone with ciltacabtagene autoleucel. Dual targeting should eventually be compared in large phase 3 trials with the classical approach of serial treatment with monotargeting agents with target switch.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032536","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:59:26Z","timestamp":1769723966000},"page":"2176-2193","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Dual-antigen\u2013targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam University Medical Center Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2026050711214955900_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026050711214955900_bib2","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"22","key":"2026050711214955900_bib3","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026050711214955900_bib4","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"10297","key":"2026050711214955900_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2026050711214955900_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026050711214955900_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","article-title":"Cevostamab in patients with heavily pretreated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study demonstrate clinically meaningful activity and manageable safety and inform the doses and regimen for combination studies [abstract]","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026050711214955900_bib8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO-24-01785","article-title":"Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: an updated analysis","volume":"43","author":"Jurgens","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026050711214955900_bib9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026050711214955900_bib10","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2026050711214955900_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/2643-3230.BCD-24-0354","article-title":"Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the US Myeloma Immunotherapy Consortium","volume":"6","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2026050711214955900_bib12","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","article-title":"Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma","volume":"30","author":"Oliver-Caldes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026050711214955900_bib13","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"9","key":"2026050711214955900_bib14","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"10499","key":"2026050711214955900_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(25)00553-7","article-title":"Cancer vaccines and the future of immunotherapy","volume":"406","author":"Pail","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"2026050711214955900_bib16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2017-05-781351","article-title":"An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma","volume":"131","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2026050711214955900_bib17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"21","key":"2026050711214955900_bib18","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"2026050711214955900_bib19","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026050711214955900_bib20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"10","key":"2026050711214955900_bib21","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"issue":"15","key":"2026050711214955900_bib22","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"2026050711214955900_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"issue":"9","key":"2026050711214955900_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"485","key":"2026050711214955900_bib25","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"9","key":"2026050711214955900_bib26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2026050711214955900_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"8","key":"2026050711214955900_bib28","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2017.04.024","article-title":"A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization","volume":"25","author":"Drent","year":"2017","journal-title":"Mol Ther"},{"issue":"5","key":"2026050711214955900_bib29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"issue":"22","key":"2026050711214955900_bib30","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib31","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2019-129582","article-title":"Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase [abstract]","volume":"134","author":"Green","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib32","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-99-116898","article-title":"T cells expressing anti B-cell maturation antigen chimeric antigen receptors for plasma cell malignancies [abstract]","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026050711214955900_bib33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood-2024-204929","article-title":"Combined PD-1 and Tim-3 blockade improves the in vitro anti-myeloma activity of T cells of patients on talquetamab [abstract]","volume":"144","author":"Mouhieddine","year":"2024","journal-title":"Blood"},{"issue":"18","key":"2026050711214955900_bib35","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2026050711214955900_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2019-127309","article-title":"Translational analysis from CARTITUDE-1, an ongoing phase 1b\/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed and\/or refractory multiple myeloma (R\/R MM), indicates preferential expansion of CD8+ T cell central memory cell subset [abstract]","volume":"134","author":"Zudaire","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2026050711214955900_bib39","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"issue":"S3","key":"2026050711214955900_bib40","first-page":"S173","article-title":"T-cell activation and myeloma cell killing confirm the mode of action of RG6234, a novel GPRC5D T-cell engaging bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"Dekhtiarenko","year":"2022","journal-title":"Hemasphere"},{"issue":"9","key":"2026050711214955900_bib41","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026050711214955900_bib42","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2026050711214955900_bib43","doi-asserted-by":"crossref","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","article-title":"Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization","volume":"10","author":"Camviel","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7750","key":"2026050711214955900_bib44","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026050711214955900_bib45","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"2026050711214955900_bib46","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026050711214955900_bib47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"2026050711214955900_bib48","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"2026050711214955900_bib49","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"25","key":"2026050711214955900_bib50","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood-2025-1030","article-title":"Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers [abstract]","volume":"146","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"13","key":"2026050711214955900_bib52","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2026050711214955900_bib53","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMc2308544","article-title":"Genetic basis of relapse after GPRC5D-targeted CAR T cells","volume":"389","author":"Mi","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2026050711214955900_bib54","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.2024026622","article-title":"Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma","volume":"146","author":"Ma","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026050711214955900_bib55","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"suppl 1","key":"2026050711214955900_bib56","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood-2023-181607","article-title":"Functional characterization of GPRC5D alteration and its impact on talquetamab resistance in relapsed\/refractory multiple myeloma [abstract]","volume":"142","author":"Han","year":"2023","journal-title":"Blood"},{"key":"2026050711214955900_bib57","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S2152-2650(24)01851-2","article-title":"OA-10 impaired membrane trafficking of GPRC5D mediates resistance to anti-GPRC5D TCE [abstract]","volume":"24","author":"Lee","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl","key":"2026050711214955900_bib58","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(22)00278-6","article-title":"Point mutations in BCMA extracellular domain mediate resistance to BCMA targeting immune therapies [abstract]","volume":"22","author":"Lee","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2026050711214955900_bib59","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1158\/2643-3230.BCD-25-0005","article-title":"Timing genomic antigen loss in multiple myeloma treated with T cell-redirecting immunotherapies","volume":"6","author":"Papadimitriou","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2026050711214955900_bib60","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood-2022-157485","article-title":"RG6234: a novel 2:1 GPRC5D T cell bispecific antibody exhibits best in class potential for the treatment of multiple myeloma as a monotherapy and in combination [abstract]","volume":"140","author":"Eckmann","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2026050711214955900_bib61","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026050711214955900_bib62","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"623","key":"2026050711214955900_bib63","doi-asserted-by":"crossref","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"issue":"25","key":"2026050711214955900_bib64","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib65","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study [abstract]","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study [abstract]","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"31","key":"2026050711214955900_bib67","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2026050711214955900_bib68","doi-asserted-by":"crossref","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"- S194: teclistamab (TEC) + nirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): the phase 1B Majestec-2 Study","volume":"7","author":"Offner","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"2026050711214955900_bib69","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2024027616","article-title":"Boosting CAR T-cell efficacy by blocking proteasomal degradation of membrane antigens","volume":"147","author":"Rieger","year":"2026","journal-title":"Blood"},{"issue":"16 suppl","key":"2026050711214955900_bib70","article-title":"Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial results from the LINKER-MM2 trial [abstract]","volume":"43","author":"Manier","year":"2025","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026050711214955900_bib71","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026050711214955900_bib72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026050711214955900_bib73","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood-2025-701","article-title":"Safety and efficacy of talquetamab + teclistamab in patients with Relapsed\/Refractory multiple myeloma from phase 1b of Redirectt-1: results with an extended median follow-up of 3 years [abstract]","volume":"146","author":"Mateos","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026050711214955900_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2514752","article-title":"Dual tgargeting of extramedullary myeloma with talquetamab and teclistamab","volume":"394","author":"Kumar","year":"2026","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026050711214955900_bib75","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2025-698","article-title":"Efficacy and safety of talquetamab + teclistamab in patients with relapsed\/refractory multiple myeloma and extramedullary disease: updated phase 2 results from the Redirectt-1 study with extended follow-up [abstract]","volume":"146","author":"Usmani","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib76","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2024-207674","article-title":"Preclinical proof-of-concept of an mRNA-based T cell engager targeting BCMA, FcRH5, and GPRC5D for the treatment of multiple myeloma [abstract]","volume":"144","author":"Garnaas","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib77","first-page":"456-456","article-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"key":"2026050711214955900_bib78","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"2026050711214955900_bib79","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","article-title":"T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA","volume":"35","author":"van de Donk","year":"2023","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"2026050711214955900_bib80","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"issue":"16 suppl","key":"2026050711214955900_bib81","article-title":"Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed\/refractory multiple myeloma (RRMM)\u2014dose escalation (DE) results [abstract]","volume":"43","author":"Lichtman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2026050711214955900_bib82","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results [abstract]","volume":"43","author":"van de Donk","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib83","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2025-3922","article-title":"Determinants of response of the BCMA\/GPRC5D-dual-targeting T-cell redirecting trispecific antibody JNJ-5322 in multiple myeloma [abstract]","volume":"146","author":"O Neill","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026050711214955900_bib84","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025030027","article-title":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models","volume":"147","author":"Pillarisetti","year":"2026","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib85","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2025-4042","article-title":"Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA\u00d7GPRC5D\u00d7CD3 trispecific antibody, in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"146","author":"Krishnan","year":"2025","journal-title":"Blood"},{"issue":"16 suppl","key":"2026050711214955900_bib86","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma [abstract]","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026050711214955900_bib87","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"2026050711214955900_bib88","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1182\/blood-2024-199733","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up and selected high-risk subgroup analyses of the Linker-MM1 Study [abstract]","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026050711214955900_bib89","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026050711214955900_bib90","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2026050711214955900_bib91","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2026050711214955900_bib92","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"2026050711214955900_bib93","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/leu.2017.302","article-title":"A compound chimeric antigen receptor strategy for targeting multiple myeloma","volume":"32","author":"Chen","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2026050711214955900_bib94","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/2326-6066.CIR-24-1313","article-title":"Bicistronic CAR T cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited","volume":"13","author":"Rodr\u00edguez-Lobato","year":"2025","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"2026050711214955900_bib95","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/blood.2024025536","article-title":"Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells","volume":"146","author":"Kasap","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026050711214955900_bib96","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/ajh.27469","article-title":"Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy","volume":"99","author":"Qi","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"2026050711214955900_bib97","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","article-title":"BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial","volume":"18","author":"Yao","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib98","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood-2025-255","article-title":"Sequential BCMA and GPRC5D CAR-T cell therapy combined with an optimizing bridging regimen for relapsed\/refractory multiple myeloma with bulky\/extensive extramedullary disease: a synergistic integration approach [abstract]","volume":"146","author":"Cheng","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026050711214955900_bib99","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":"suppl 2","key":"2026050711214955900_bib100","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S2152-2650(25)03465-2","article-title":"OA-71 - concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells for the treatment of relapsed or refractory multiple myeloma: results from the phase I TANDEMM Clinical Trial [abstract]","volume":"25","author":"Mailankody","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2026050711214955900_bib101","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"issue":"1","key":"2026050711214955900_bib102","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"2026050711214955900_bib103","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI insight"},{"key":"2026050711214955900_bib104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-020-00192-6","article-title":"Characterization of novel dual tandem CD19\/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma","volume":"8","author":"Kang","year":"2020","journal-title":"Biomark Res"},{"issue":"16 suppl","key":"2026050711214955900_bib105","article-title":"Updated results of a phase I, open-label study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"41","author":"Du","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"2026050711214955900_bib106","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma [abstract]","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib107","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1182\/blood-2025-269","article-title":"Safety and efficacy of AZD0120, a BCMA\/CD19 dual-targeting CAR T-cell therapy, in relapsed\/refractory multiple myeloma: preliminary results from the DURGA-1 phase 1b\/2 study [abstract]","volume":"146","author":"Richard","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib108","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2024-204774","article-title":"Autologous B cell maturation antigen (BCMA) and CD19 dual targeting Fastcar-T cells (GC012F\/AZD0120) as first-line therapy for elderly patients with newly diagnosed multiple myeloma patients [abstract]","volume":"144","author":"Du","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026050711214955900_bib109","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamaoncol.2024.2172","article-title":"B-cell maturation antigen\/CD19 dual-targeting immunotherapy in newly diagnosed multiple myeloma","volume":"10","author":"Qiang","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026050711214955900_bib110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2026050711214955900_bib111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med"},{"issue":"20","key":"2026050711214955900_bib112","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of b-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026050711214955900_bib113","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"suppl 1","key":"2026050711214955900_bib114","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2024-201356","article-title":"Efficacy and safety with extended follow-up in a phase 1 study of BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with heavily pretreated relapsed\/refractory (RR) multiple myeloma (MM) [abstract]","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib115","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2024-203279","article-title":"BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with relapsed\/refractory (RR) multiple myeloma (MM) and 1-3 prior regimens: updated phase 1 safety and efficacy results [abstract]","volume":"144","author":"Bal","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib116","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2025-270","article-title":"First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: clinical outcomes and biological correlates of disease response and resistance [abstract]","volume":"146","author":"Graham","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026050711214955900_bib117","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"2026050711214955900_bib118","doi-asserted-by":"crossref","first-page":"1422478","DOI":"10.3389\/fimmu.2024.1422478","article-title":"Case report: dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma","volume":"15","author":"Shi","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"2026050711214955900_bib119","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41375-023-02065-x","article-title":"Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma","volume":"38","author":"Li","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026050711214955900_bib120","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026050711214955900_bib121","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026050711214955900_bib122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib123","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1182\/blood-2024-211334","article-title":"Preclinical analysis of ciltacabtagene autoleucel combination strategies with T cell bispecifics and daratumumab to support optimization of clinical benefit in myeloma patients [abstract]","volume":"144","author":"Marvel","year":"2024","journal-title":"Blood"},{"issue":"17","key":"2026050711214955900_bib124","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026050711214955900_bib125","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026050711214955900_bib126","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026050711214955900_bib127","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjh.19505","article-title":"French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): a real-world IFM study from the DESCAR-T registry","volume":"205","author":"Ferment","year":"2024","journal-title":"Br J Haematol"},{"issue":"11","key":"2026050711214955900_bib128","doi-asserted-by":"crossref","first-page":"e70260","DOI":"10.1002\/hem3.70260","article-title":"Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: practical guidance from the European Myeloma Network","volume":"9","author":"van de Donk","year":"2025","journal-title":"Hemasphere"},{"issue":"14","key":"2026050711214955900_bib129","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026050711214955900_bib130","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S2152-2650(24)01929-3","article-title":"P-026 combined GPRC5D and BCMA-targeted T-cell redirecting therapy in the treatment of RRMM","volume":"24","author":"Godby","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026050711214955900_bib131","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S2152-2650(24)01930-X","article-title":"P-027 real world experience of standard of care talquetamab in patients with relapsed and refractory multiple myeloma","volume":"24","author":"Grajales-cruz","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026050711214955900_bib132","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2024-210451","article-title":"Efficacy of anti-BCMA CAR-T cell therapies in multiple myeloma patients with prior exposure to bispecific antibodies- results from a Retrospective Multi-Center Registry Analysis [abstract]","volume":"144","author":"Waldschmidt","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib133","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2025-699","article-title":"Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the \u201cSTEM\u201d (Sequential T Cell-Engagement for Myeloma) trial [abstract]","volume":"146","author":"Cohen","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026050711214955900_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009048","article-title":"CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression","volume":"13","author":"Arroyo-R\u00f3denas","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"14","key":"2026050711214955900_bib135","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026050711214955900_bib136","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2026050711214955900_bib137","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"2026050711214955900_bib138","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1016\/S2352-3026(25)00048-1","article-title":"Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Xia","year":"2025","journal-title":"Lancet Haematol"},{"key":"2026050711214955900_bib139","author":"Kumar","year":"13  2024"},{"issue":"1","key":"2026050711214955900_bib140","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"2026050711214955900_bib141","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S2152-2650(24)01842-1","article-title":"OA-01 talquetamab (tal) + daratumumab (dara) + pomalidomide (pom) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the phase 1b TRIMM-2 Study","volume":"24","author":"Bahlis","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026050711214955900_bib142","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026050711214955900_bib143","author":"Perrot","year":"14  2025"},{"issue":"8","key":"2026050711214955900_bib144","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"24","key":"2026050711214955900_bib145","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood.2025029360","article-title":"Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study","volume":"146","author":"Chari","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026050711214955900_bib146","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"1","key":"2026050711214955900_bib147","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"issue":"20","key":"2026050711214955900_bib148","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026050711214955900_bib149","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.hoc.2023.12.012","article-title":"Impact of clonal heterogeneity in multiple myeloma","volume":"38","author":"Schinke","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2026050711214955900_bib150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2026050711214955900_bib151","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","article-title":"T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment","volume":"5","author":"van de Donk","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"586","key":"2026050711214955900_bib152","doi-asserted-by":"crossref","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"issue":"7","key":"2026050711214955900_bib153","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/2326-6066.CIR-23-0692","article-title":"The CD33xCD123xCD70 multispecific CD3-engaging DARPin MP0533 induces selective T cell-mediated killing of AML leukemic stem cells","volume":"12","author":"Bianchi","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"suppl 1","key":"2026050711214955900_bib154","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood-2024-199211","article-title":"MP0533 (CD33 x CD123 x CD70 x CD3), a tetra-specific CD3-engaging Darpin for the treatment of patients with relapsed\/refractory AML or MDS\/AML: results of an ongoing phase 1\/2a study [abstract]","volume":"144","author":"Jongen-Lavrencic","year":"2024","journal-title":"Blood"},{"issue":"16 suppl","key":"2026050711214955900_bib155","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"41","author":"van de Donk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026050711214955900_bib156","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1182\/blood-2024-199423","article-title":"MBS314, a G protein-coupled receptor family C group 5 member D (GPRC5D) x B-cell maturation antigen (BCMA) x CD3 trispecific antibody, in relapsed and\/or refractory multiple myeloma (RRMM): preliminary results from a phase \u2160, first-in-human, open-label, dose escalation study [abstract]","volume":"144","author":"An","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib157","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2025-702","article-title":"Initial results of the first-in-human phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma [abstract]","volume":"146","author":"Li","year":"2025","journal-title":"Blood"},{"issue":"7 suppl","key":"2026050711214955900_bib158","article-title":"Abstract 1875: a novel T-cell-engaging therapeutical antibody against GPRC5D&BCMA for multiple myeloma treatment [abstract]","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2026050711214955900_bib159","doi-asserted-by":"crossref","first-page":"3381.2","DOI":"10.1182\/blood-2024-200737","article-title":"A phase I first-in-human, open-label trial to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SIM0500, a humanized GPRC5D-BCMA-CD3 trispecific antibody, in participants with relapsed or refractory multiple myeloma [abstract]","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"issue":"8 suppl 1","key":"2026050711214955900_bib160","article-title":"Abstract 2135: QLS4131, a proprietary T cell engager targeting both BCMA and GPRC5D for the treatment of multiple myeloma [abstract]","volume":"85","author":"Yang","year":"2025","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"2026050711214955900_bib161","first-page":"A1196","article-title":"1075 Bispecific and trispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma [abstract]","volume":"12","author":"Roth","year":"2024","journal-title":"J ImmunoTherapy Cancer"},{"issue":"7 suppl","key":"2026050711214955900_bib162","doi-asserted-by":"crossref","first-page":"LB128","DOI":"10.1158\/1538-7445.AM2024-LB128","article-title":"Abstract LB128: A novel tri-specific T cell engager targeting BCMA and GPRC5D for treatment of multiple myeloma [abstract]","volume":"84","author":"Tan","year":"2024","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2026050711214955900_bib163","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2021-152160","article-title":"Preclinical assessment of CDR101 - a BCMAxCD3xPD-L1 trispecific antibody with superior anti-tumor efficacy [abstract]","volume":"138","author":"Vrohlings","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2026050711214955900_bib164","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1182\/blood-2024-204614","article-title":"First-in-human phase 1 study of SAR442257 in patients with relapsed\/refractory multiple myeloma and non-Hodgkin lymphoma [abstract]","volume":"144","author":"Schjesvold","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026050711214955900_bib165","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/cells13100879","article-title":"Pre-clinical assessment of SAR442257, a CD38\/CD3xCD28 trispecific T cell engager in treatment of relapsed\/refractory multiple myeloma","volume":"13","author":"Grab","year":"2024","journal-title":"Cells"},{"issue":"3","key":"2026050711214955900_bib166","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after daratumumab and BCMA-targeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"6","key":"2026050711214955900_bib167","doi-asserted-by":"crossref","first-page":"e006699","DOI":"10.1136\/jitc-2023-006699","article-title":"Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2176\/2517392\/blood_bld-2025-032536-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/19\/2176\/2517392\/blood_bld-2025-032536-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:22:19Z","timestamp":1778167339000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/19\/2176\/566335\/Dual-antigen-targeting-T-cell-immunotherapies-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":167,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032536","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,7]]},"published":{"date-parts":[[2026,5,7]]}}}